Cargando…
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
With the growing burden of metabolic disease, cardiovascular disease, and diabetes mellitus, there is an implication for new pharmacological intervention. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a class of drugs that work on SGLT2 receptors in the kidneys to decrease glucose reabsorpt...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937770/ https://www.ncbi.nlm.nih.gov/pubmed/36819350 http://dx.doi.org/10.7759/cureus.33939 |